{
  "swe262_clinical_study": {
    "swe262_official_title": "Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial",
    "swe262_required_header": {
      "swe262_link_text": "Link to the current ClinicalTrials.gov record.",
      "swe262_url": "https://clinicaltrials.gov/show/NCT03874338",
      "swe262_download_date": "ClinicalTrials.gov processed this data on July 19, 2020"
    },
    "swe262_location_countries": {
      "swe262_country": "United States"
    },
    "swe262_condition": [
      "Neutrophils.Hypersegmented | Bld-Ser-Plas",
      "STEMI - ST Elevation Myocardial Infarction"
    ],
    "swe262_overall_status": "Recruiting",
    "swe262_secondary_outcome": [
      {
        "swe262_time_frame": "between baseline and 3 months",
        "swe262_description": "Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)",
        "swe262_measure": "Other soluble markers of neutrophil activity"
      },
      {
        "swe262_time_frame": "between baseline and 3 months",
        "swe262_description": "Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1Î²)",
        "swe262_measure": "Markers of systemic inflammation"
      },
      {
        "swe262_time_frame": "between baseline and 3 months",
        "swe262_description": "Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)",
        "swe262_measure": "Neutrophil-driven responses that may further propagate injury"
      }
    ],
    "swe262_intervention": {
      "swe262_intervention_name": "Colchicine Pill",
      "swe262_intervention_type": "Drug",
      "swe262_description": "Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.",
      "swe262_arm_group_label": [
        "Colchicine",
        "Placebo"
      ]
    },
    "swe262_has_expanded_access": "No",
    "swe262_last_update_submitted_qc": "September 10, 2019",
    "swe262_arm_group": [
      {
        "swe262_arm_group_label": "Colchicine"
      },
      {
        "swe262_arm_group_label": "Placebo"
      }
    ],
    "swe262_completion_date": {
      "type": "Anticipated",
      "content": "February 1, 2022"
    },
    "swe262_number_of_groups": 2,
    "swe262_id_info": {
      "swe262_org_study_id": "18-01323",
      "swe262_nct_id": "NCT03874338",
      "swe262_secondary_id": "1R01HL146206"
    },
    "swe262_study_type": "Observational",
    "swe262_brief_summary": {
      "swe262_textblock": "CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of"
    },
    "swe262_sponsors": {
      "swe262_lead_sponsor": {
        "swe262_agency_class": "Other",
        "swe262_agency": "NYU Langone Health"
      },
      "swe262_collaborator": [
        {
          "swe262_agency_class": "Other",
          "swe262_agency": "Population Health Research Institute"
        },
        {
          "swe262_agency_class": "NIH",
          "swe262_agency": "National Heart, Lung, and Blood Institute (NHLBI)"
        }
      ]
    },
    "swe262_responsible_party": {
      "swe262_investigator_title": "Assistant Professor of Medicine",
      "swe262_investigator_full_name": "Binita Shah",
      "swe262_responsible_party_type": "Principal Investigator",
      "swe262_investigator_affiliation": "NYU Langone Health"
    },
    "swe262_source": "NYU Langone Health",
    "swe262_study_first_submitted_qc": "March 12, 2019",
    "swe262_last_update_posted": {
      "type": "Actual",
      "content": "September 12, 2019"
    },
    "swe262_oversight_info": {
      "swe262_has_dmc": "No",
      "swe262_is_fda_regulated_drug": "No",
      "swe262_is_fda_regulated_device": "No"
    },
    "swe262_brief_title": "CLEAR SYNERGY Neutrophil Substudy",
    "swe262_intervention_browse": {
      "swe262_mesh_term": "Colchicine"
    },
    "swe262_overall_official": {
      "swe262_role": "Principal Investigator",
      "swe262_affiliation": "NYU School of Medicine",
      "swe262_last_name": "Binita Shah, MD"
    },
    "swe262_enrollment": {
      "type": "Anticipated",
      "content": 670
    },
    "swe262_study_first_submitted": "March 12, 2019",
    "swe262_overall_contact_backup": {
      "swe262_last_name": "Binita Shah, MD"
    },
    "swe262_overall_contact": {
      "swe262_email": "fatmira.curovic@nyumc.org",
      "swe262_last_name": "Fatmira Curovic",
      "swe262_phone": "646-501-9648"
    },
    "swe262_eligibility": {
      "swe262_gender": "All",
      "swe262_study_pop": {
        "swe262_textblock": "Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial"
      },
      "swe262_criteria": {
        "swe262_textblock": "Inclusion Criteria:"
      },
      "swe262_minimum_age": "19 Years",
      "swe262_healthy_volunteers": "No",
      "swe262_sampling_method": "Non-Probability Sample",
      "swe262_maximum_age": "110 Years"
    },
    "swe262_study_first_posted": {
      "type": "Actual",
      "content": "March 14, 2019"
    },
    "swe262_study_design_info": {
      "swe262_observational_model": "Other",
      "swe262_time_perspective": "Prospective"
    },
    "swe262_location": {
      "swe262_facility": {
        "swe262_name": "NYU School of Medicine",
        "swe262_address": {
          "swe262_zip": 10016,
          "swe262_country": "United States",
          "swe262_city": "New York",
          "swe262_state": "New York"
        }
      },
      "swe262_contact": {
        "swe262_email": "fatmira.curovic@nyumc.org",
        "swe262_last_name": "Fatmira Curovic",
        "swe262_phone": "646-501-9648"
      },
      "swe262_contact_backup": {
        "swe262_last_name": "Binita Shah, MD"
      },
      "swe262_status": "Recruiting"
    },
    "swe262_condition_browse": {
      "swe262_mesh_term": [
        "Myocardial Infarction",
        "ST Elevation Myocardial Infarction",
        "Infarction"
      ]
    },
    "swe262_primary_outcome": {
      "swe262_time_frame": "between baseline and 3 months",
      "swe262_description": "Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups.",
      "swe262_measure": "soluble L-selectin"
    },
    "swe262_start_date": {
      "type": "Actual",
      "content": "March 4, 2019"
    },
    "swe262_patient_data": {
      "swe262_sharing_ipd": "No"
    },
    "swe262_primary_completion_date": {
      "type": "Anticipated",
      "content": "February 1, 2021"
    },
    "swe262_verification_date": "September 2019",
    "swe262_last_update_submitted": "September 10, 2019"
  }
}